JenniferRuthBrownMDPhD

PubMed

• Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
  Alessandra Tedeschi, Leyla Mohseninejad, Keri Yang, Sheng Xu, Aileen Cohen, Swetha Challagulla, Mei Xue, Rhys Williams, Susan M O'Brien, Constantine Tam, Mazyar Shadma...> ;Blood Cancer Journal. 2024 May 2
• 1 citations
  Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
  Barr, P. M., Barr, P. M., Barr, P. M., Jennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, Cecelia Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Na...> ;Blood. 2024 Apr 18
• Clinical Risks for Chronic Lymphocytic Leukemia.
  Jennifer R Brown> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 1
• Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
  Richard R Furman, Constantine S Tam, Joe-Elie Salem, Aileen Cohen, Meng Zhang, Jun Zhang, Lipeng Chen, Han Ma, Javid J Moslehi, Christopher R Flowers, Jennifer R Brown> ;Blood Advances. 2024 Mar 19
• Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis o...
  Brown, J., Ghia, P., Jurczak, W., Kahl, B., Lamanna, N., Robak, T., Shadman, M., Tam, C., Qiu, L., Paik, J., Salmi, T., Wang, L., Zhang, J., Zhang, M., Cohen, A., Ma, ...> ;Haematologica. 2024 Feb 29
• Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care.
  Mary Ann Anderson, Renata Walewska, Fidelma Hackett, Arnon P Kater, Josie Montegaard, Susan O'Brien, John F Seymour, Matthew Smith, Stephan Stilgenbauer, Ashley Whitec...> ;Cancers. 2024 Feb 28
• Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.
  Ahn, I., Brander, D., Ren, Y., Zhou, Y., Tyekucheva, S., Walker, H., Black, R., Montegaard, J., Alencar, A., Shune, L., Omaira, M., Jacobson, C., Armand, P., Ng, S., C...> ;Blood Advances. 2024 Feb 27
• Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL.
  Mashima, K., Fernandes, S., Naeem, A., Shupe, S., Fardoun, R., Brown, J., Davids, M.> ;Research Square. 2024 Jan 16
• Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
  Jennifer R Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak, Nicole Lamanna, Susan M O'Brien, Constantine S Tam, Lugui Qiu, Keshu Zhou, Ma...> ;Future Oncology. 2024 Apr 1
• ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
  Arribas, A., Napoli, S., Cascione, L., Barnabei, L., Sartori, G., Cannas, E., Gaudio, E., Tarantelli, C., Mensah, A., Spriano, F., Zucchetto, A., Rossi, F., Rinaldi, A...> ;Molecular Cancer Therapeutics. 2024 Mar 4
• A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
  Reid W Merryman, Robert A Redd, Arnold S Freedman, Inhye E Ahn, Jennifer R Brown, Jennifer L Crombie, Matthew S Davids, David C Fisher, Eric D Jacobsen, Austin I Kim, ...> ;Annals of Hematology. 2024 Jan 1
• Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and...
  Constantine S Tam, Nicole Lamanna, Susan M O'Brien, Lugui Qiu, Keri Yang, Gisoo Barnes, Ken Wu, Tommi Salmi, Jennifer R Brown> ;Current Medical Research and Opinion. 2023 Sep 27
• Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab.
  Paolo Ghia, Gisoo Barnes, Keri Yang, Constantine S Tam, Tadeusz Robak, Jennifer R Brown, Brad S Kahl, Tian Tian, Andy Szeto, Jason C Paik, Mazyar Shadman> ;Current Medical Research and Opinion. 2023 Sep 27
• Localized upper extremity edema secondary to Bruton's tyrosine kinase inhibition.
  Bonnie W Leung, Christopher J Fay, Jordan T Said, Anthony R Sheets, Christine G Lian, Jennifer R Brown, Jorge J Castillo, Shayna Sarosiek, Catherine Flynn, Nicole R Le...> ;Leukemia & Lymphoma. 2023 Dec 1
• 66 citations
  PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
  Antonino Glaviano, Aaron S C Foo, Hiu Y Lam, Kenneth C H Yap, William Jacot, Robert H Jones, Huiyan Eng, Madhumathy G Nair, Pooyan Makvandi, Birgit Geoerger, Matthew H...> ;Molecular Cancer. 2023 Aug 18
• 18 citations
  Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
  John F Seymour, John C Byrd, Paolo Ghia, Arnon P Kater, Asher Chanan-Khan, Richard R Furman, Susan O'Brien, Jennifer R Brown, Talha Munir, Anthony Mato, Stephan Stilge...> ;Blood. 2023 Aug 24
• 13 citations
  Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
  Aishath Naeem, Filippo Utro, Qing Wang, Justin Cha, Mauno Vihinen, Stephen Martindale, Yinglu Zhou, Yue Ren, Svitlana Tyekucheva, Annette S Kim, Stacey M Fernandes, Go...> ;Blood Advances. 2023 May 9
• 2 citations
  Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
  Jasneet Kaur Khalsa, Justin Cha, Filippo Utro, Aishath Naeem, Ishwarya Murali, Yanan Kuang, Kevin Vasquez, Liang Li, Svitlana Tyekucheva, Stacey M Fernandes, Lauren Ve...> ;Blood. 2023 Aug 3
• 3 citations
  METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL.
  Yiming Wu, Meiling Jin, Mike Fernandez, Kevyn L Hart, Aijun Liao, Xinzhou Ge, Stacey M Fernandes, Tinisha McDonald, Zhenhua Chen, Daniel Röth, Lucy Y Ghoda, Guido Marc...> ;Blood Cancer Discovery. 2023 May 1
• 3 citations
  Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
  Mazyar Shadman, Beenish S Manzoor, Kavita Sail, Hande H Tuncer, John N Allan, Chaitra Ujjani, Nnadozie Emechebe, Rajesh Kamalakar, Catherine C Coombs, Lori Leslie, Pau...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jul 1
• Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors.
  Deepti Gadi, Stephen P Martindale, Pui Yan Chiu, Jasneet Khalsa, Pei-Hsuan Chen, Stacey M Fernandes, Zixu Wang, Svitlana Tyekucheva, John-Hanson Machado, David C Fishe...> ;Blood Cancer Journal. 2023 Feb 2
• Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.
  Merryman, R., Michaud, L., Redd, R., Mondello, P., Park, H., Spilberg, G., Robertson, M., Taranto, E., Ahmed, G., Chase, M., Jeter, E., Ahn, I., Brown, J., Crombie, J....> ;Hemasphere. 2023 Feb 1
• 1 citations
  A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
  Christine E Ryan, Danielle M Brander, Paul M Barr, Svitlana Tyekucheva, Liam R Hackett, Mary C Collins, Stacey M Fernandes, Yue Ren, Yinglu Zhou, Mikaela M McDonough, ...> ;Leukemia. 2023 Apr 1
• 81 citations
  Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
  Jennifer R Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak, Nicole Lamanna, Susan M O'Brien, Constantine S Tam, Lugui Qiu, Keshu Zhou, Ma...> ;The New England Journal of Medicine. 2023 Jan 26
• 22 citations
  Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome.
  Erin M Parry, Ignaty Leshchiner, Romain Guièze, Connor Johnson, Eugen Tausch, Sameer A Parikh, Camilla Lemvigh, Julien Broséus, Sébastien Hergalant, Conor Messer, Fili...> ;Nature Medicine. 2023 Jan 1
• Join now to see all

Abstracts/Posters

• Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
  Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
  Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Resu...
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)
  Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
  Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
  Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with InvestigatorÍs Choice of ... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• The Future of Chronic Lymphocytic Leukemia (CLL) Therapy 
  60th American Society of Hematology Annual Meeting - 12/3/2018
• Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• 17th International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma® 
  Physicians' Education Resource, LLC, New York, New York - 2/15/2013
• Join now to see all